# Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma

> **NCT04840875** · PHASE1 · COMPLETED · sponsor: **Beijing Boren Hospital** · enrollment: 16 (actual)

## Conditions studied

- T Cell Lymphoma
- T-cell Leukemia

## Interventions

- **BIOLOGICAL:** chimeric antigen receptor T cell treatment

## Key facts

- **NCT ID:** NCT04840875
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-14
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840875, "Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04840875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*